of junB expression is consistently found in AML patients and all lineages of mature cells were dramatically reduced in number. Together, these results indicate that expressing high levels of HoxA9 (Dorsam et al., 2003) . Together, these findings suggest that junB inactivation raising JunB levels in LT-HSC decreases the frequency of stem cells. could be important for MPD development and perhaps overt myeloid leukemia including CML.
Here, we use the junB ϩ /GFP ϩ spleen cells to assay the inUbi-junB transgenic mice, with considerably lower levels in the myeloid progenitor populations (CMP, GMP, and crease in junB levels provided by the lentiviral transduction ( Figure 1C) . At 20 weeks post-transplantation, we MEP) and B cells, and no expression in mature granulocytes. Strikingly, a similar analysis performed on populadetermined the distribution of transduced Ly5.2 ϩ /GFP ϩ cells in the stem, progenitor, and mature compartments tions isolated from 6-to 9-month-old junB Ϫ/Ϫ Ubi-junB mice showed dramatically reduced expression levels of of recipient mice (Figures 1D-1F ). Although transduction with the junB(L) lentivirus resulted in a modest 1.8-fold the Ubi-junB transgene in every cell type, including LT-HSC, and, consequently, a major reduction in total junB increase in total junB mRNA levels, dramatically reduced numbers of HSC-derived Ly5.2 ϩ /GFP ϩ cells were found mRNA levels in the entire hematopoietic system of the junB
Ubi-junB mice ( Figure 2C ). Inactivation of the in the bone marrow, spleen, and thymus of the transplanted mice. Furthermore, in the bone marrow, almost Ubi-junB transgene in the myeloid lineage of junB
UbijunB mice has been described previously (Passegué et 
